DNA methylation markers for oral pre-cancer progression: A critical review

Oral Oncol. 2016 Feb:53:1-9. doi: 10.1016/j.oraloncology.2015.11.012. Epub 2015 Dec 12.

Abstract

Although oral cancers are generally preceded by a well-established pre-cancerous stage, there is a lack of well-defined clinical and morphological criteria to detect and signal progression from pre-cancer to malignant tumours. We conducted a critical review to summarize the evidence regarding aberrant DNA methylation patterns as a potential diagnostic biomarker predicting progression. We identified all relevant human studies published in English prior to 30th April 2015 that examined DNA methylation (%) in oral pre-cancer by searching PubMed, Web-of-Science and Embase databases using combined key-searches. Twenty-one studies (18-cross-sectional; 3-longitudinal) were eligible for inclusion in the review, with sample sizes ranging from 4 to 156 affected cases. Eligible studies examined promoter region hyper-methylation of tumour suppressor genes in pathways including cell-cycle-control (n=15), DNA-repair (n=7), cell-cycle-signalling (n=4) and apoptosis (n=3). Hyper-methylated loci reported in three or more studies included p16, p14, MGMT and DAPK. Two longitudinal studies reported greater p16 hyper-methylation in pre-cancerous lesions transformed to malignancy compared to lesions that regressed (57-63.6% versus 8-32.1%; p<0.01). The one study that explored epigenome-wide methylation patterns reported three novel hyper-methylated loci (TRHDE; ZNF454; KCNAB3). The majority of reviewed studies were small, cross-sectional studies with poorly defined control groups and lacking validation. Whilst limitations in sample size and study design preclude definitive conclusions, current evidence suggests a potential utility of DNA methylation patterns as a diagnostic biomarker for oral pre-cancer progression. Robust studies such as large epigenome-wide methylation explorations of oral pre-cancer with longitudinal tracking are needed to validate the currently reported signals and identify new risk-loci and the biological pathways of disease progression.

Keywords: Bio-marker; CpG sites; DNA methylation; Diagnostic marker; Epigenetics; Leukoplakia; Oral pre-cancer; Oral sub-mucous fibrosis; Promoter regions; Tumour suppressor genes.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Apoptosis / physiology
  • Biomarkers, Tumor / physiology*
  • Cell Cycle / physiology
  • Child
  • Cross-Sectional Studies
  • DNA Methylation / physiology*
  • DNA Repair
  • Disease Progression*
  • Early Detection of Cancer / methods
  • Evidence-Based Medicine*
  • Female
  • Genes, Tumor Suppressor / physiology
  • Humans
  • Male
  • Middle Aged
  • Mouth Neoplasms / pathology*
  • Precancerous Conditions / diagnosis
  • Precancerous Conditions / pathology*
  • Promoter Regions, Genetic / physiology
  • Young Adult

Substances

  • Biomarkers, Tumor